blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1



Wednesday, 27 October 2010

Roger Cleghorn of RC:D London - not exactly a suffering seroxater

Search Results[PDF] 2005 Investor Relations Society Conference Sponsorship Proposal


File Format: PDF/Adobe Acrobat - Quick View

Adrian. Clarke. Financial Times. Charlotte Phillips. Hemscott. Timothy Clegg. UBS. Helen. Pickford. Royal Sun Alliance. Roger. Cleghorn. RC:D London Ltd ...

www.ir-soc.org.uk/files/.../IRS_DL_sponsorship_form_Jan05.PDF - Similar

Fiddaman is CCHR shill - read his words - Am I a Commissioner for CCHR? No, but I sure would like to be

Is the agenda of the CCHR to convert people to a religion or is it to create awareness with regard to the safety of patient care?




Watch this DVD and you will have your answer.



Am I a Commissioner for CCHR? No, but I sure would like to be. They are at the forefront of raising awareness about this fraudulent industry and if that means someone labelling me a Scientologist then that is a very small price to pay for someone else's ignorance.



You can watch the full length documentary' and purchase other feature length documentaries by clicking on the 'Dead Wrong' tab in the player, here.

Monday, 25 October 2010

Mad Pride Welfare Benefits & Services Protest "24 Hour Medication Strike" Caution Warning - October 25th - 26th 2010 - madpride.org.uk

Mad Pride Welfare Benefits & Services Protest "24 Hour Medication Strike" Caution Warning - October 25th - 26th 2010 - madpride.org.uk


http://the-uk-seroxat-litigation-chronicles.blogspot.com/





Reposting the following Caution Warning - anyone considering supporting this protest by joining the "24 hour medication strike" please think very carefully - no psychiatric medications should be stopped abruptly, missing doses is putting you, your health, safety and possibly liberty at risk. Please support the protest, but not this way -



thanks Tues



****

Saturday, 9 October 2010





Mad Pride Welfare Benefits & Services Protest Warning madpride.org.uk



Slightly off topic – but It has come to my attention that MadPride.org.uk are organising a protest at Speaker’s Corner, Hyde Park, London on Tuesday October 26th 2010 at 1 pm –



“A Public Execution and Assorted Horrors"

"A Demonstration against Cuts to Benefits and Services”

Promoted in their press release asincluding the promotion of



“A day of action to appose welfare benefit cuts for people labelled mentally ill”

including the promotion of



“A 24 hour nationwide medication strike!”

Whilst the sentiments of the protest against cuts to welfare benefit for the mentally ill is commendable, this suggested action –



given the nature of both the side effects caused by missed doses and the consequences of rapid withdrawal associated with powerful psychiatric drugs that all, including severely mentally ill patients, will be taking –



is irresponsible and possibly dangerous.



For years a few members of Yahoo group UKSurvivors have made great efforts to raise awareness of the dangers psychiatric drugs pose in relation to side effects, missed doses and withdrawal –



which Mark Roberts the groups owner, madpride.org.uk’s founder member, protest and “24 hour medication strike” promoter - has consciously and deliberately chosen to ignore,



whilst putting in place the following Blog, Forum and Twitter accounts to promote his protest campaign and “The 24 hour medication strike”



http://madpride.org.uk/blogs/madprideblog/



http://madpride.org.uk/forum/index.php



http://twitter.com/madpridemark



Please, by all means support the protest – BUT please, under NO circumstances follow the promoted course of action or encourage others on medication to join “the 24 hour medication strike“ - as it may have dire and possibly tragic consequences.



Tuesday

---

Posted by Tuesday

Evelyn Pringle’s articles removed from OpEd

http://cannonfire.blogspot.com/2008/10/who-is-evelyn-pringle-and-why-is.html


This is the first I heard of this.




I did not write my articles because I was a Hillary supporter. I wrote my articles because my investigation turned up what it did, even though I was absolutely not looking or expecting what I found. As a journalist and as a human being, I could not not write about what I found just because I am a Democrat!!!



I find it very disturbing that Rob would even consider such an outright censorship of truthful information.



Shortly after I wrote my first article, I put out a commentary of sorts saying that if anyone found one factual statement that was false or incorrect to contact me and show me where it was wrong and I would make a correction.



NOT ONE PERSON contacted with a single example of an untrue or false statement in any of the 11 articles I wrote.



I will be outraged if Rob removes those articles and I will make it known! I spent 2 and a half months of my life, unpaid, 12 and 18 hours a day 7 days a week, investigating the matters I wrote about and if he does something like this to me I will never forgive him.



The articles are up in full on Scoop and several other websites so if he pulls this, their removal from OpEd will stick out like a sore thumb on the internet

http://therealbarackobama.wordpress.com/2008/10/13/if-this-is-a-sign-of-things-to-come-were-in-big-trouble/

"Seroxat should not be stopped suddenly" - clear advice from MHRA June 2003

Seroxat should not be stopped suddenly because of the risk of withdrawal reactions.
The dose should be reduced very gradually, using half tablets, and then alternating
days, if necessary. If the dose is not tapered, there is a greater chance of experiencing
side effects. For the majority of people, symptoms go away on their own within 2
weeks. If side effects are intolerable on dose reduction or stopping, the dose should be
increased and subsequently reduced more gradually.
 
 
http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019507.pdf
 
 
source - MESSAGE FROM PROFESSOR G DUFF, CHAIRMAN OF COMMITTEE ON SAFETY OF MEDICINES

10 June 2003

Sunday, 24 October 2010

Seroxat P.I.L. 1995 - under 18 years old DO NOT TAKE - the Evidence is clear

If you answer "YES" to any of the following questions, DO NOT take this medicine. Go back to your doctor and ask what to do:



Are you allergic to paroxetine?

Are you pregnant or may you be pregnant soon?

Are you breast feeding?

Are you under 18?

Do you have kidney o, liver trouble?

Do you have heart trouble?

Do you suffer from epilepsy or mania (overactive and sometimes violent behaviour)?

http://www.itri.brighton.ac.uk/projects/pills/corpus/PIL/data/SmithKline_Beecham/Seroxat/Seroxat.html

Saturday, 23 October 2010

Seroxat patient leaflet 1995 - do NOT take pregnant !

BEFORE YOU TAKE ‘SEROXAT’




If you answer "YES" to any of the following questions, DO NOT take this medicine. Go back to your doctor and ask what to do:



Are you allergic to paroxetine?

Are you pregnant or may you be pregnant soon?

Are you breast feeding?

Are you under 18?

Do you have kidney o, liver trouble?

Do you have heart trouble?

Do you suffer from epilepsy or mania (overactive and sometimes violent behaviour)?

Most people find that 'Seroxat' does not affect their normal daily lives. But, as with many medicines you should take extra care when you ere driving or operating machinery



http://www.itri.brighton.ac.uk/projects/pills/corpus/PIL/data/SmithKline_Beecham/Seroxat/Seroxat.html

Seroxat 1993 note high incidence of withdrawal reports from GP's - source Dr Healy

Seroxat & Withdrawal - 3





From shortly after the licensing of this drug on the UK market, the Medicines Control Agency was flooded with reports of withdrawal problems for Seroxat. In 1993, the Drug Safety Research Unit study of Seroxat noted a high frequency of general practitioner reporting of withdrawal problems – although the DSRU suggested without making clear the basis for this suggestion that this high frequency of withdrawal problems did not indicate dependence.



http://webcache.googleusercontent.com/search?q=cache:YsLW-UngSNAJ:www.socialaudit.org.uk/58092-DH.htm+seroxat+1993&cd=12&hl=en&ct=clnk&gl=uk

extract from

SSRIs & WITHDRAWAL/DEPENDENCE

BRIEFING PAPER: 20-06-2003
DAVID HEALY


http://www.socialaudit.org.uk/58092-DH.htm

Friday, 22 October 2010

Seroxat Seroquel® or Zyprexa® - Dr's protect from predatory lawyers

A Simple Way to Avoid Malpractice Litigation


Jeffrey A. Lieberman, MD



Authors and Disclosures



Posted: 10/21/2010



Share

Facebook Twitter

processing....



http://www.medscape.com/viewarticle/730542





Hello, this is Dr. Jeffrey Lieberman of Columbia University speaking for Medscape. The title of this commentary could be, "Physician, Protect Thyself." Recently, I recorded a Medscape blog in which I commented on being very disappointed to see advertisements by personal injury lawyers, looking for patients who had taken second generation antipsychotic drugs like Seroquel® or Zyprexa®They were seeking clients on whose behalf they could file lawsuits.



On the basis of this, I described how physicians need to be aware of the predatory nature of these legal practices and ensure that there is adequate documentation of the rationale for using these treatments and how to advise patients about the potential risks for the medications they are about to receive.



Recently, I was reading the newspaper and saw the report of a settlement between Novartis and the US Justice Department for improper marketing practices for the use of Trileptal® off-label. This follows in the wake of settlements by other pharmaceutical companies with the US Justice Department and the US Food and Drug Administration (FDA), including Lilly, Pfizer, and Astra Zeneca, for infractions in terms of marketing practices for the use of medications, and non-FDA indicated uses (off-label uses).



This raises another aspect of the vulnerability that physicians have to potential legal actions. I just wanted to amplify that concern and tell people my thoughts on that and hope that it can be useful, in terms of protecting physicians' practices against such consequences. Basically, we treat patients with a variety of therapeutic techniques, including medications. Medications are approved by the FDA for specific indications.



When we use these medications, we use them for their therapeutic effects, but virtually all medications have some side effects. When starting, or adjusting, the dose of medications we need to advise patients of the potential consequences, in terms of, side effects, reiterate the rationale for using the medication, and document this in the medical record so that it's clearly stated.



In addition, it is an essential part of medical practice to be able to use medications for illnesses or conditions other than those that are indicated by FDA approval. This is common practice in all areas of medicine. Indeed, sponsors (pharmaceutical companies) are not going to pursue indications for all of the purposes for which their products can be used.



Physicians, in using medications for non-indicated or off-label purposes, need to have an adequate justification for this, in terms of evidence in the literature that justifies the use, or at the very least, a scientific or medical rationale for the use of the medication. It is important to document this in the medical record, so that if there is a question about the purpose of the medication, or whether there was undue influence by a pharmaceutical company (as opposed to having a rationale, in terms of clinical practice evidence in the literature for efficacy, or a pharmacologic rationale for why the drug would be useful for a given patient), this can be reflected in the medical record.



It's unfortunate that we have to be so vigilant for potential assaults on our clinical practice and we have to practice defensive medicine, but such is the world that we live in, so it behooves us as physicians to protect ourselves by documenting our presentations to patients about the risks and benefits of treatment, and (if we are using the medication for a non-FDA indicated purpose, an off-label use of the medication) the rationale for this use.



This will enable you to think through the steps, in terms of prescribing a treatment, whether it's on-label or off-label, and at the same time, it will also serve as a protective practice, in terms of reducing legal liability. This routine, this set of procedures, can be made habitual and systematized. It's a little like the book by our colleagues, Atul Gwand, who wrote about the "checklist approach" to medicine as a way of reducing medical errors and trying to emulate the way that aeronautical engineers and pilots manage their procedures in a very routine, systematic way with a series of checklists.



Physicians can do the same when prescribing of treatments, and in this way, physicians can both ensure that they are thorough, as well as reduce their legal liability. Those are my comments for today -- this is Dr. Jeffrey Lieberman of Columbia University for Medscape.



[ CLOSE WINDOW ]

[CLOSE WINDOW]Authors and DisclosuresAuthor(s)Jeffrey A. Lieberman, MD Professor and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY; Psychiatrist in Chief, New York Presbyterian Hospital, New York, NY



Disclosure: Jeffrey A. Lieberman, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bioline; Cephalon, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Intra-Cellular Therapies, Inc.; Janssen PharmaceuticaProducts, L.P. (US); Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Psychogenics; Wyeth Pharmaceuticals Inc.

Received grants for clinical research from: Allon; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, L.P. (US); Merck & Co. Inc; Pfizer Inc; Wyeth Pharmaceuticals Inc.

Served on the DSMB for: Solvay Pharmaceuticals, Inc.

Received patents from: Repligen Corporation

Wednesday, 20 October 2010

Seroxat Joe puts Seroxat ahead of all the other brands just like Seroxat Sarah - venal

Bob Fiddaman said


"I can see no benefit of Seroxat, none whatsoever. The longer it remains on the market will mean countless suffering for people on other SSRi's. Once removed, it will open the doors for other SSRi's to be thoroughly investigated and maybe other bloggers, campaigners, advocates can start banging the drum and asking the regulator about Prozac, Zoloft and other SSRi related drugs."

http://fiddaman.blogspot.com/2009/08/seroxat-in-media.html

Tuesday, 19 October 2010

Another Seroxat Liar M/s Venn "saw Seroxat banned in under 18 year olds"

"Over the years more has become known about Seroxat. In my time on the Seroxat Users Group committee, I saw Seroxat banned in under 18 year olds, GSK issue a warning that 1 in four patients will suffer withdrawal problems, the patient information leaflet double in size and listed side-effects. "

http://news.bbc.co.uk/1/hi/programmes/panorama/3710528.stm



extract from -
Seven years of struggle by Sarah Venn Seroxat user
 Sunday, 3 October, 2004,

Sarah Venn barrister wanted Seroxat personal experiences considered but NOT the other brands!!

The Users Group remains concerned, however, that the MCA has still not agreed to consider the personal experiences of Seroxat users in the review of the drug. Sarah Venn said: “We have offered to provide the MCA with all the information we have gathered about adverse reactions, dependence and withdrawal reactions, but they have not decided how or even if they will include patients’ experiences in the review. That is extremely worrying and we will continue to press them on this important point.”






http://webcache.googleusercontent.com/search?q=cache:YNIwlocOuhQJ:www.seroxatusergroup.org.uk/Documents/jw0328%2520ssri%2520review%2520panel%2520dissolved.doc+goodrelations+seroxatusergroup&cd=10&hl=en&ct=clnk&gl=uk&client=firefox-a

Monday, 18 October 2010

Seroxat counterpoint blog

This counterpoint blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

Is the Seroxat Group Action Litigation Order no: 68 Compromised by its Own Defining Issue?

The UK Seroxat Group Action Litigation, Order No:68, is being brought under the Consumer Protection Act 1987 (CPA)

http://the-uk-seroxat-litigation-chronicles.blogspot.com/2010/10/is-seroxat-group-action-litigation.html




“A product is defective if, at the time of circulation, it is not as "safe as persons generally are entitled to expect," taking account of a number of factors including any instructions or warnings provided with the product and the manner in which it has been marketed.”

In proving a case of a “defective product” the only need is to show the product – in this case GlaxoSmithKline’s (GSK) drug Seroxat (Seroxat UK, Paxil USA) - was not up to consumers’ expectations.However, lead Lawyer Mark Harvey of Hugh James Solicitors, Cardiff has chosen to include a Defining Issue stipulation that any adverse effects and discontinuation, withdrawal difficulties suffered by the Seroxat “user” has to be



“to a greater extent than all other Selective Serotonin Re-uptake Inhibitors (SSRIs)”

HM Courts Service: Seroxat Group Litigation Order no: 68.

The report of the Committee on Safety of Medicines (CSM), Expert Working Group (EWG) on SSRI Antidepressants, published December 2004, found all drugs in the class lacking in safety, efficacy and causing discontinuation problems in up to 80% of consumers.


It’s unclear why the “stipulation” has been included, as The CSM Expert Working Group report on all SSRI Antidepressants effectively proved the Group Action litigants case against GSK by finding their product Seroxat not being as "safe as persons generally are entitled to expect,".

December 2004, Seroxat Group Action Litigation case proved and won -

baring lead lawyer Mark Harvey’s inclusion of the apparently unnecessary and possibly untenable Defining Issue “stipulation”.


To prove the Seroxat Group Action by justifying the included “stipulation” raises the need to examine criteria that differentiate the drugs in the SSRI, SNRI class within the restricted Defining Issue of discontinuation, withdrawal and drug classification.



This depends on the two theories of what causes discontinuation and withdrawal and the issues of selectivity nature, affinity and potency; dose related drug action classification; definition by acronym classification; and external evidence.



All interrelate, and other than the issue of selectivity nature, affinity and potency, focus on two drugs in the class the SSRI paroxetine (Seroxat) and SNRI venlafaxine (Wyeth, Efexor UK, Effexor USA).



The CSM EWG into SSRI Antidepressants used pharmacological characteristics and the 1999 Tatsumi et al study to compare Half-life and the Potency and Affinity of the drugs on the central nervous system neurotransmitters. Finding all drugs have binding affinities to different monoamine transporters, primary effects on different receptors and cause secondary changes in receptor numbers and receptor function at the synapse.



1 - The issue of selectivity nature, affinity and potency is the most complicated – defining whether Seroxat is worse than any other drug in the class by comparing drugs with different intrinsic values that despite their acronym name classification titles i.e. SSRI, SNRI etc - are not “pharmacologically “clean”” or defined in action of selectivity “to the Serotonin system”, all also affecting to varying degrees noradrenalin and dopamine. This aspect is covered in more detail here.





The Tatsumi et al study results are valued using Kd or dissociated constant – as explained on the table the lower the Kd the higher the affinity to the transporter.



Affinity Kd ratings show –

Paroxetine (Seroxat) has the highest affinity to Serotonin at 0.1 - just point 0.2 higher that Sertraline (Pfizer, Lustral UK, Zoloft USA) the second highest at 0.3.



Potency findings published by CSM, EWG are not clear because they have not stated whether they are rating Potency on the Affinity to Serotonin alone or Serotonin (5HT), Noradrenalin (NA) and dopamine (DA).



Potency rating show –

Paroxetine (Seroxat) is the “most potent” with the “lowest selectivity” and Sertraline (Lustral) the “second most potent”.



However, when comparing the Affinity and Potency with other drugs in the class - that all to varying degrees effect 5HT, NA and DA and as Paroxetine (Seroxat) is the least selective and only has a negligible 0.2 higher Affinity to Serotonin than Sertraline (Lustral), total Affinity and Potency Kd values to 5HT, NA and DA could be used to assess this point.



Combined Kd Affinity and Potency values to Serotonin (5HT), Noradrenalin (NA) and Dopamine (DA) show –



Sertraline (Lustral) has the highest combined Affinity and Potency with a Kd 445.3 and the least selective Paroxetine (Seroxat) is second highest with a combined Kd of 530.1.



2 - The two theories of what causes discontinuation and withdrawal is explained by Dr David Healy in the “HALTING SSRIs” document, one theory is the shorter half-life of paroxetine (Seroxat) and venlafaxine (Efexor) makes these drugs more problematic, the second theory is regarding the potency of paroxetine and venlafaxine. This aspect is covered in more detail here.



If according to the first theory - which includes a switch to fluoxetine (Ely Lilly Prozac UK and USA) Half-life 1 to 4 days - the cause of discontinuation and withdrawal is dependant on the shortness of Half-life - venlafaxine (Efexor) has the shortest Half-life of 5 hours - paroxetine (Seroxat) is considerably longer at 20 hours.



The second theory - which includes a switch to citalopram (Lundbeck, Cipramil, Celexa) Kd 1.2 - with regard paroxetine (Seroxat) and venlafaxine (Efexor) being “relatively more potent serotonin reuptake inhibitors” is possibly itself called into question by the findings of the CSM, EWG and Tatsumi et al study as venlafaxine has a Kd value of 152 making it, other than mirtazapine, the least “potent serotonin reuptake inhibitor” of the drugs studied.



This possibly places the whole onus of discontinuation and withdrawal problems inherent with all drugs in the SSRI, SNRI class back on a drugs Half-life as citalopram’s Half-life at 36 hours, is longer than both paroxetine (Seroxat) and venlafaxine (Efexor) – and would possibly benefit some as with the fluoxetine switch.



3 - The dose related drug action classification issue, Wyeth are the only manufacturer of those drugs studied to have specified that their drug works on more than one neurotransmitter, however it is the opinion of Dr David Healy in the “HALTING SSRIs” document and the MHRA that although Venlafaxine is named by the acronym SNRI it’s mode of action is that of an SSRI up to doses of 150 mg, over this it has an additional mode of action to become a serotonin and noradrenalin reuptake inhibitor. This aspect is covered in more detail here



4 - The drug definition by acronym classification title by definition the difference between an SSRI and an SNRI should be dependant on selectivity and potency of action i.e. to serotonin or noradrenalin. In the case of the SSRI, SNRI drug class no drug is “selective” to one monoamine transporter, all drugs effect serotonin and noradrenalin, paroxetine (Seroxat) with Kd of 40 to the noradrenalin transporter has a considerably higher affinity than venlafaxine at a NA of Kd 9400. This aspect is covered in more detail here.



5 - The issue of external evidence, as covered briefly here, is dependant on the MHRA, Yellow Card Scheme adverse drug reports and media coverage that has influenced those reports. The MHRA has received considerably more adverse event reports for paroxetine (Seroxat) than any other drug in the class, however, the December 2004 CSM). EWG Report drew attention to the influence of the media coverage and a number of obviously duplicated reports made with regard paroxetine (Seroxat) and it has been noted that BBC Panorama published and issued it’s own Yellow Cards that were accepted by the MHRA.



I will return to the influence of media coverage, the BBC, Panorama, UK Government officials and departments, the Seroxat User Group.org and Hugh James Solicitors in more depth in future posts - but the media coverage has had a profound influence on this aspect, as the Richard M Martin, Margaret May, and David Gunnell, Department of Social Medicine, University of Bristol study “Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004” shows.







Is the UK Seroxat Group Action Litigation, Order No:68 compromised by Lead Lawyer of Hugh James, Cardiff, Mark Harvey’s included Defining Issue “stipulation”?

1 - Does an Affinity and Potency to serotonin of Kd 0.2 higher than Sertraline (Lustral) make Paroxetine (Seroxat) the worst drug in the class …. or does the highest combined Affinity and Potency Kd to serotonin, noradrenalin and dopamine make Sertraline (Lustral) a worse drug than the least selective Paroxetine (Seroxat)?

2 - If the theory is that discontinuation and withdrawal is caused by the drugs short Half-life …. does SNRI venlafaxine’s (Efexor) half-life of 5 hours make it more difficult to withdraw from than the SSRI Paroxetine’s (Seroxat)?In proving a case of a “defective product” the only need is to show the product – in this case GlaxoSmithKline’s (GSK) drug Seroxat (Seroxat UK, Paxil USA) - was not up to consumers’ expectations.

3 - Is Wyeth’s honest mode of action classification of venlafaxine (Efexor) being an Serotonin Noradrenalin Reuptake Inhibitor (SNRI), although acting as an Selective Serotonin Reuptake Inhibitor (SSRI) in doses up to 150 mg, likely to be disregarded as the SSRI Paroxetine’s (Seroxat) has the highest Affinity and Potency Kd to noradrenalin of any SSRI, SNRI studied?

4 - Can a drugs classification be defined by a catchy marketing tool or will the acronym SNRI be overruled by the scientific facts?

5 – Has the unprecedented media coverage and in particular the BBC’s Panorama issued Yellow Cards damaged the integrity of the MHRA, the system and the case dependant adverse events report evidence?

Seroxat - Paxil NOT habit forming says Paxilprogress founder Darcy Baston

Darcy Baston of Paxilprogress said "I believe that Paxil is not habit forming"


Hereʼs why: for a drug to be labelled habit forming, you have
to demonstrate a drug seeking behavior often at the expense
of rationality, safety, and economic feasibility. This means
you have to be highly desiring of the drug for the sake of
having the drug. This isnʼt quite the case with Paxil.



see



http://www.paxilprogress.org/pdf/Paxil-Withdrawal-Guide-2005.pdf

Sunday, 17 October 2010

Seroxat Spitzer suit - part of industry wide agenda

Kevin Scotcher, an analyst at SG Securities, said the attorney general has a "much bigger agenda". Mr Scotcher said: "The question is, 'are consumers and doctors in possession of sufficient knowledge?' GSK pays for trials and has control over whether they are published or not. These trials are then used to sell a drug. His lawsuit is exploring something that will lead him to address conflicts of interests across the spectrum. The FDA is financed by the drug industry, for instance."




The Spitzer case will be examined to see if it sets a legal precedent - and GSK's decision to publish the trials will spark a debate over whether it, too, raises the ethical bar on publication.

http://webcache.googleusercontent.com/search?q=cache:hAQY4DjCquEJ:www.independent.co.uk/life-style/health-and-families/health-news/gsk-fights-back-in-battle-with-spitzer-over-seroxat-731788.html+GSK+fights+Seroxat+claims&cd=1&hl=en&ct=clnk&gl=uk

extracted from -
 
GSK fights back in battle with Spitzer over Seroxat

http://www.independent.co.uk/life-style/health-and-families/health-news/gsk-fights-back-in-battle-with-spitzer-over-seroxat-731788.html

£50 million pounds was spent on Benzodiazepine legal aid - yet patients got nothing in that SCAM

http://www.publications.parliament.uk/pa/cm199899/cmselect/cmhealth/549/99072723.htm

In 1993-94 the Benzodiazepine Litigation ended owing to the withdrawal of Legal Aid Board funding. Over £50 million pounds was spent on legal aid and by the drug companies. Since this event the number of prescriptions for all Sedative/Hypnotic drugs has increased by several per cent overall, and that for Valium has increased by 15 per cent (1994-97). The prescribing of the new Sedative/Hypnotic drugs Zolpidem and Zopiclone, which act on the Benzodiazepine receptors has risen dramatically and is now about two million per year. It is very significant that the number of adverse reactions (No/yr/106 pres.) reported for these drugs is very much greater (x100) than for any of the Benzodiazepines. This coincides with many reports to support groups of dependency on these drugs. It appears that the lessons of history have not been learnt and there is an additional dependency epidemic in the making.

Mark Harvey's group calimed 10,000 yet served 314 Seroxat writs - who keeps the public funded legal aid?




http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk


. It was the first antidepressant to be slapped with a suicide-risk warning. It's drawn fire--and lawsuits--from U.S. patients who say they went into withdrawal when trying to quit treatment. Now, a group of UK patients are suing GlaxoSmithKline for the same withdrawal problems, seeking up to $98,000 per patient, or $31 million-plus with the 314 patients participating so far. Of course, it's not simply the monetary damages that could hurt, but the attendant publicity, which might turn off potential patients

Hugh James dropped 97% clients who should contact SRA Fraud and Confidential Intelligence Bureau

Fraud and Confidential Intelligence Bureau is dedicated to gathering information and intelligence, operating in accordance with the National Intelligence Model.


http://www.sra.org.uk/solicitors/scams/fraud-dishonesty.page

BBC Panorama / Shelley Jofre KNOWINGLY put lives at risk to support Hugh James Seroxat only litigation









2.30 in Jofre says - ” read a little bit in news paper about patients complaints” year 2000 about ” Seroxat difficult to withdraw from” .. Jofre found it intriguing Jofre had only just started working on Panorama at that stage




3.30 in ” Jofre calls SSRI’s “SELECTIVE Serotonin Reuptake Inhibitors”



4.14 Jofre knew little of how the pharmcutical industry worked



4 .30 in Ed says - lets look at antidepressant story



4 45 Jofre says although problems with whole class of antidepressants we (bbc) decided to concentrate on Seroxat Why we narrowed down on Seroxat 1 because it was made by GSK 2 all the drugs in class cause suicidal thinking on dose change 3 Seroxat had a unique problem of withdrawal BECAUSE IT WAS LONGER ACTING … we decided to focus research into this drug



6.00 in - 40 min Panorama film took Shelley Jofre 8 months to make



6.10 in - It’s not something you do lightly WE WERE TAKING ON the worlds second largest drug company



7.30 We were talking to the lawyer the whole way through production



9.30 in - Jofre says “we took a punt” on Dr David Healy